<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737931</url>
  </required_header>
  <id_info>
    <org_study_id>243-12-002</org_study_id>
    <nct_id>NCT01737931</nct_id>
  </id_info>
  <brief_title>A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject</brief_title>
  <official_title>An Open-Label Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of symptomatic therapy with topical steroids and antihistamines
      for application site reaction (ASR) after administration of SPM 962 in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Irritation Score of the Application Site</measure>
    <time_frame>24 hours after 2 mg/24 hr patch removal</time_frame>
    <description>Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment.
The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)</measure>
    <time_frame>24 hours after 2 mg/24 hr patch removal</time_frame>
    <description>Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment.
The score ranges from 0 (no itching) to 100 (strongest imaginable itching).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Irritation Score After Patch Removal</measure>
    <time_frame>Up to 72 hours after patch removal</time_frame>
    <description>Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching of Application Site Evaluated by VAS After Patch Removal</measure>
    <time_frame>Up to 96 hours after patch removal</time_frame>
    <description>Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods).
The score ranges from 0 (no itching) to 100 (strongest imaginable itching).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Topical Steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical antihistamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment to the application sites after the patch removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical steroid (Dexamethasone)</intervention_name>
    <description>for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal</description>
    <arm_group_label>Topical Steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical antihistamine (Diphenhydramine)</intervention_name>
    <description>for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal</description>
    <arm_group_label>Topical antihistamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male or female and aged between 20 and 45 years of age (inclusive)

          -  Subject is of normal body weight as determined by a body-mass index (BMI) between 18
             and 28 kg/m2

          -  Subject is healthy as determined by EA (medical history, physical examination, skin
             evaluation, vital signs, ECG, hematology, clinical chemistry, urinalysis)

          -  Subject is surgically sterile; subject has been postmenopausal for at least 12
             consecutive months if female; or subject agrees to remain abstinent or to follow two
             acceptable methods of birth control from EA to the end of observation period. (fore
             male and female subjects)

        Exclusion Criteria:

          -  Subject has a history or complication of epilepsy and/or seizures

          -  Subject has clinically relevant changes in the ECG, such as second- or third-degree AV
             block, a complete bundle branch block, prolongation of the QRS complex over 120 ms, or
             of the QTcB (QT interval corrected for HR by Bazett´s formula) over 500 ms at EA

          -  Subject has a clinically relevant hepatic dysfunction

          -  Subject has a clinically relevant renal dysfunction

          -  Subject has a history of significant skin hypersensitivity to adhesives or other
             transdermal products or recent unresolved contact dermatitis

          -  Subject has a history or complication of atopic or eczematous dermatitis, psoriasis,
             and/or an active skin disease or skin tumors

          -  Subject has more than 1 known or suspected drug hypersensitivity, in particular to any
             component of the trial medication

          -  Subject has a history of chronic alcohol or drug abuse within the last 5 years

          -  Subject is tested positive for HIV-1/2Ab, HBsAg or HCV-Ab

          -  Subject tests positive for alcohol and/or drugs at EA

          -  Subject is taking any prohibited concomitant medication

          -  Subject has a history or complication of narrow angle glaucoma

          -  Subject has a history or complication of respiratory or cardiovascular disorders
             (e.g., heart failure, coronary heart disease, hypertension, arrhythmia,
             tachyarrhythmia, or myocardial infarction)

          -  Subject has a history or complication of psychic abnormality, psychiatric or
             neurologic illness, or autonomic neuropathy

          -  Subject has a history or complication of diabetes mellitus and/or thyroid dysfunction,
             especially hyperthyroidism or other endocrine disorders

          -  Subject has a history or complication of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoji Imaoka, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Kyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <results_first_submitted>February 9, 2014</results_first_submitted>
  <results_first_submitted_qc>March 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2014</results_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPM 962</keyword>
  <keyword>rotigotine</keyword>
  <keyword>application site reaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 120 eligible subjects received the IMP treatment at least once, and 3 of them were withdrawn from the trial before topical treatment allocation due to subject request (1 subject) and for lack of efficacy evaluation (2 subjects).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Topical Steroid</title>
          <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
        </group>
        <group group_id="P2">
          <title>Topical Antihistamine</title>
          <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
        </group>
        <group group_id="P3">
          <title>No-treatment</title>
          <description>No treatment to the application sites after the patch removal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Steroid</title>
          <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
        </group>
        <group group_id="B2">
          <title>Topical Antihistamine</title>
          <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
        </group>
        <group group_id="B3">
          <title>No-treatment</title>
          <description>No treatment to the application sites after the patch removal</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="4.2"/>
                    <measurement group_id="B2" value="26.7" spread="4.8"/>
                    <measurement group_id="B3" value="26.1" spread="3.7"/>
                    <measurement group_id="B4" value="26.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Skin Irritation Score of the Application Site</title>
        <description>Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment.
The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.</description>
        <time_frame>24 hours after 2 mg/24 hr patch removal</time_frame>
        <population>Full analysis set (FAS) subjects with a score of ≥ 0.5 (±) at Day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Steroid</title>
            <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
          </group>
          <group group_id="O2">
            <title>Topical Antihistamine</title>
            <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
          </group>
          <group group_id="O3">
            <title>No-treatment</title>
            <description>No treatment to the application sites after the patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Irritation Score of the Application Site</title>
          <description>Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment.
The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.</description>
          <population>Full analysis set (FAS) subjects with a score of ≥ 0.5 (±) at Day 3</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.237" lower_limit="0.084" upper_limit="0.390"/>
                    <measurement group_id="O2" value="0.289" lower_limit="0.136" upper_limit="0.422"/>
                    <measurement group_id="O3" value="0.250" lower_limit="0.101" upper_limit="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)</title>
        <description>Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment.
The score ranges from 0 (no itching) to 100 (strongest imaginable itching).</description>
        <time_frame>24 hours after 2 mg/24 hr patch removal</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Steroid</title>
            <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
          </group>
          <group group_id="O2">
            <title>Topical Antihistamine</title>
            <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
          </group>
          <group group_id="O3">
            <title>No-treatment</title>
            <description>No treatment to the application sites after the patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)</title>
          <description>Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment.
The score ranges from 0 (no itching) to 100 (strongest imaginable itching).</description>
          <population>FAS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.5" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-0.7" upper_limit="1.6"/>
                    <measurement group_id="O3" value="0.9" lower_limit="-0.2" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Irritation Score After Patch Removal</title>
        <description>Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.</description>
        <time_frame>Up to 72 hours after patch removal</time_frame>
        <population>FAS subjects with a score of ≥ 0.5 (±) at Day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Steroid</title>
            <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
          </group>
          <group group_id="O2">
            <title>Topical Antihistamine</title>
            <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
          </group>
          <group group_id="O3">
            <title>No-treatment</title>
            <description>No treatment to the application sites after the patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Irritation Score After Patch Removal</title>
          <description>Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.</description>
          <population>FAS subjects with a score of ≥ 0.5 (±) at Day 3</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>- (1 hour after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± (1 hour after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+ (1 hour after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="38.9"/>
                    <measurement group_id="O3" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- (24 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9"/>
                    <measurement group_id="O2" value="52.6"/>
                    <measurement group_id="O3" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± (24 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="36.8"/>
                    <measurement group_id="O3" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+ (24 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="10.5"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- (48 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="94.7"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± (48 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- (72 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="94.7"/>
                    <measurement group_id="O3" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± (72 hours after patch removal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itching of Application Site Evaluated by VAS After Patch Removal</title>
        <description>Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods).
The score ranges from 0 (no itching) to 100 (strongest imaginable itching).</description>
        <time_frame>Up to 96 hours after patch removal</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Steroid</title>
            <description>Topical medication of steroid (Dexamethasone) to the application sites after the patch removal</description>
          </group>
          <group group_id="O2">
            <title>Topical Antihistamine</title>
            <description>Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal</description>
          </group>
          <group group_id="O3">
            <title>No-treatment</title>
            <description>No treatment to the application sites after the patch removal</description>
          </group>
        </group_list>
        <measure>
          <title>Itching of Application Site Evaluated by VAS After Patch Removal</title>
          <description>Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods).
The score ranges from 0 (no itching) to 100 (strongest imaginable itching).</description>
          <population>FAS</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 hours after patch removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="6.9"/>
                    <measurement group_id="O2" value="-3.0" spread="9.0"/>
                    <measurement group_id="O3" value="-2.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after patch removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="7.9"/>
                    <measurement group_id="O2" value="-3.3" spread="8.6"/>
                    <measurement group_id="O3" value="-2.3" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after patch removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="10.0"/>
                    <measurement group_id="O2" value="-2.6" spread="7.0"/>
                    <measurement group_id="O3" value="-2.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after patch removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="10.5"/>
                    <measurement group_id="O2" value="-3.6" spread="9.0"/>
                    <measurement group_id="O3" value="-2.9" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours after patch removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="10.0"/>
                    <measurement group_id="O2" value="-3.8" spread="8.9"/>
                    <measurement group_id="O3" value="-3.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours after patch removal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="10.1"/>
                    <measurement group_id="O2" value="-3.8" spread="8.9"/>
                    <measurement group_id="O3" value="-3.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Over-all</title>
          <description>In this study, all the subjects were received SPM962 with the same dose and regimen during the acceleration and dose-escalation periods and then they were randomized into one of the three groups after removal of SPM962 to evaluate recovery of skin reaction caused by SPM962 using either steroids, antihistamine or no treatment.
Since AEs mainly occurred in the acceleration and dose-escalation periods when SPM962 were used, AEs are shown in one group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA(15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research and Development</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

